Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May 28:6:88.
doi: 10.3389/fendo.2015.00088. eCollection 2015.

Identifying Common Genetic Risk Factors of Diabetic Neuropathies

Affiliations
Review

Identifying Common Genetic Risk Factors of Diabetic Neuropathies

Ini-Isabée Witzel et al. Front Endocrinol (Lausanne). .

Abstract

Type 2 diabetes mellitus (T2DM) is a global public health problem of epidemic proportions, with 60-70% of affected individuals suffering from associated neurovascular complications that act on multiple organ systems. The most common and clinically significant neuropathies of T2DM include uremic neuropathy, peripheral neuropathy, and cardiac autonomic neuropathy. These conditions seriously impact an individual's quality of life and significantly increase the risk of morbidity and mortality. Although advances in gene sequencing technologies have identified several genetic variants that may regulate the development and progression of T2DM, little is known about whether or not the variants are involved in disease progression and how these genetic variants are associated with diabetic neuropathy specifically. Significant missing heritability data and complex disease etiologies remain to be explained. This article is the first to provide a review of the genetic risk variants implicated in the diabetic neuropathies and to highlight potential commonalities. We thereby aim to contribute to the creation of a genetic-metabolic model that will help to elucidate the cause of diabetic neuropathies, evaluate a patient's risk profile, and ultimately facilitate preventative and targeted treatment for the individual.

Keywords: cardiac autonomic neuropathy; diabetic complications; diabetic neuropathy; diabetic peripheral neuropathy; genetic factors; type 2 diabetes mellitus; uremic neuropathy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The multifactorial etiology of the diabetic neuropathies.
Figure 2
Figure 2
The effects of common genetic variants implicated in the diabetic neuropathies. The gene products of ACE, AKR1B1, APOE, MTHFR, NOS3, and VEGF are all involved in important molecular pathways that have been associated with type 2 diabetes (T2DM) and diabetic neuropathies. Certain genetic variants of these genes have been identified as risk factors for diabetic nephropathy (DN) and diabetic peripheral neuropathy (DPN) in particular. DN causes renal damage and a build-up of uremic toxins, which is thought to lead to uremic neuropathy (UN), suggesting that these genetic risk factors also affect the onset and progression of UN. The same genetic variants have also been implied in diabetic autonomic neuropathy and cardiac complications, suggesting their involvement in CAN, but their direct association with CAN in T2DM patients remains to be proven. Solid black arrows indicate that a statistically significant association has been published; dashed gray arrows indicate a suspected association.

References

    1. International Diabetes Federation. IDF Diabetes Atlas [Internet]. 6th ed (2013). Available from: http://www.idf.org/diabetesatlas
    1. Khandoker AH, Jelinek HF, Moritani T, Palaniswami M. Association of cardiac autonomic neuropathy with alteration of sympatho-vagal balance through heart rate variability analysis. Med Eng Phys (2010) 32(2):161–7. 10.1016/j.medengphy.2009.11.005 - DOI - PubMed
    1. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev (2011) 27(7):639–53. 10.1002/dmrr.1239 - DOI - PubMed
    1. Wilson N, Wright D. Inflammatory mediators in diabetic neuropathy. J Diabetes (2011) S5:004. 10.4172/2155-6156.S5-004 - DOI
    1. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care (2010) 33(10):2285–93. 10.2337/dc10-1303 - DOI - PMC - PubMed